Rocket Pharmaceuticals (RCKT) Current Assets (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Current Assets data on file, last reported at $149.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 53.83% year-over-year to $149.8 million; the trailing twelve-month figure through Mar 2026 stood at $149.8 million (down 53.83% YoY), and the FY2025 full-year result was $192.7 million, down 49.04% from the prior year.
• Current Assets declined to $149.8 million in Q1 2026, from $192.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $446.9 million in Q3 2023 to a low of $149.8 million in Q1 2026.
• A 5-year average of $309.4 million and a median of $324.5 million in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets soared 43.63% in 2023 and slumped 53.83% in 2026, its largest moves.
• Tracing RCKT's Current Assets over 5 years: stood at $364.1 million in 2022, then gained by 3.89% to $378.2 million in 2023, then decreased by 0.01% to $378.2 million in 2024, then tumbled by 49.04% to $192.7 million in 2025, then fell by 22.26% to $149.8 million in 2026.
• Business Quant data shows RCKT's Current Assets at $149.8 million in Q1 2026, $192.7 million in Q4 2025, and $227.7 million in Q3 2025.